NCT02158975 · OUTCOME

Duration of Response

Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas · Source last updated 2017-11-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: months
Interval / dispersion: Not reported
Time frame: 24 months after initiation of study treatment

What was measured

Time from documentation of tumor response to disease progression.

Analysis population: Although 12 patients were analyzable, only one patient responded to treatment and therefore only 1 patient is represented for the duration of response.

Groups in this outcome

MLN9708

MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
MLN9708	1

Reported measurements

Source class 1

Values in months · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
MLN9708	12	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
12

denoms

counts
group Id
OG000
value
1
units
Participants

description

Time from documentation of tumor response to disease progression.

groups

description
MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.
id
OG000
title
MLN9708

param Type

NUMBER

population Description

Although 12 patients were analyzable, only one patient responded to treatment and therefore only 1 patient is represented for the duration of response.

reporting Status

POSTED

time Frame

24 months after initiation of study treatment

title

Duration of Response

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice